Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing ophthalmic and other specialty therapeutics built around lotilaner and related formulations. Its business combines a marketed eye-care product, XDEMVY, with a pipeline that includes product candidates for ocular rosacea and Lyme disease prophylaxis.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved prescription eye-care therapy sold for Demodex blepharitis.
Development programs for ocular rosacea and related eye conditions.
Revenue from out-licensing and clinical supply arrangements.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products98,4 %
- License and Collaboration1,6 %
Lähde: 10-K FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Tarsus sells primarily to eye care professionals who prescribe XDEMVY for patients with Demodex blepharitis. Its commercial model also depends on payers and pharmacy channels that determine access, coverage, and patient affordability. In development programs, the company’s future customers would include ophthalmologists, dermatology-adjacent specialists, and patients with ocular inflammatory conditions if approvals are obtained.
Ophthalmologists and optometrists prescribe XDEMVY and drive adoption through diagnosis and treatment decisions.
Patients buy the therapy through prescriptions to treat a specific eyelid condition and related symptoms.
Commercial insurers, Medicare, and Medicaid affect formulary access and out-of-pocket affordability.
Specialty and dispensing channels fulfill prescriptions and support commercial reach.
Specialists who may adopt TP-04 or TP-05 if those programs reach approval.
Strategia
Tarsus is focused on expanding XDEMVY adoption in Demodex blepharitis while maintaining regulatory, manufacturing, and supply continuity. It is also building a broader ophthalmology pipeline around TP-04 and TP-05 and may use collaborations or licensing to extend reach and fund development. Protecting intellectual property and expanding commercial infrastructure are central to its strategy because the company competes in a crowded specialty-pharma market.
The approved product is the main revenue engine and validates the category.
Additional approved products would diversify revenue and reduce single-product dependence.
Commercial continuity depends on reliable lotilaner supply and drug product manufacturing.
Patent and licensing strength support pricing power and future collaboration value.
Maantiede
Tarsus is headquartered in the United States and generates most of its commercial activity there through XDEMVY. The company also has a China out-license and clinical supply agreement that contributes collaboration revenue, while manufacturing and supply chain activities rely on third-party partners, including some outside the U.S. Geography matters because the business is concentrated in the U.S. commercial eye-care market but exposed to cross-border manufacturing, regulatory, and licensing arrangements.
Riskit
Tarsus is exposed to single-product concentration, clinical development risk, and dependence on third-party manufacturers and suppliers. As a biopharmaceutical company, it also faces regulatory, reimbursement, intellectual property, and competitive risks that can affect adoption, pricing, and the timing of future approvals.
- Single-product dependenceVaikutus: KorkeaTodennäköisyys: Korkea
Most commercial revenue is tied to XDEMVY, so any slowdown would materially affect results.
Kohdistuu: Commercial sales concentration
- Manufacturing and supplier concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has relied on a limited number of suppliers and CMOs for lotilaner and drug product.
Kohdistuu: API and fill-finish supply
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Matala
TP-04 and TP-05 are still in development and may not show sufficient efficacy or safety.
Kohdistuu: Pipeline programs
- Reimbursement and access riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Coverage decisions by commercial and government payers affect prescription volume and net sales.
Kohdistuu: Commercial access
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Other prescription and off-label treatments can limit market share and pricing power.
Kohdistuu: Ophthalmology and blepharitis market
Kirjanpito
Harkinnanvaraiset erätCommercial eye-care products often require estimates for rebates, discounts, and chargebacks that reduce gross sales to net revenue.
Vaikutus: Affects reported net product sales and quarterly comparability
China out-license and clinical supply arrangements may include milestone or performance-based recognition.
Vaikutus: Can create uneven revenue timing across periods
Commercialization of XDEMVY requires inventory build, supply commitments, and distribution costs.
Vaikutus: Can affect margins and working capital
Pipeline programs and related intangible assets depend on clinical and regulatory success.
Vaikutus: Potential write-downs if programs underperform
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
Traws Pharma, Inc.
TRAW · Pharmaceutical Preparations
Palvella Therapeutics, Inc
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
Kenvue Inc.
KVUE · Perfumes, Cosmetics & Other Toilet Preparations
XBiotech Inc.
XBIT · Pharmaceutical Preparations
Milestone Pharmaceuticals Inc.
MIST · Pharmaceutical Preparations
Päivitetty: 24.9.2026